KEYNOTE-522 Study of Pembro plus Chemo vs. Placebo plus Chemo as Neoadjuvant Treatment Followed by Pembro vs. Placebo as Adjuvant Treatment for Early TNBC: Pathologic Complete Response in Key Subgroups

被引：0
|
作者：
Schmid, P. [1 ]
机构：
[1] Barts Canc Inst, Ctr Expt Med, London, England
来源：
ANNALS OF SURGICAL ONCOLOGY | 2020年 / 27卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P38
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [41] RANDOMIZED PHASE II STUDY OF SUNITINIB (SU) PLUS ERLOTINIB (E) VS. PLACEBO (P) PLUS E FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
    Groen, H. J. M.
    Socinski, M.
    Grossi, F.
    Juhasz, E.
    Gridelli, C.
    Baas, P.
    Usari, T.
    Tye, L.
    Chao, R.
    Blumenschein, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 139 - 139
  • [42] Randomized, global, phase III study of tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update
    Hubner, R.
    Xu, J.
    Kato, K.
    Raymond, E.
    Shu, Y.
    Pan, Y.
    Jiang, Y.
    Zhang, J.
    Park, S. R.
    Kojima, T.
    Lin, C-Y.
    Gotovkin, E.
    Wyrwicz, L. S.
    Ishihara, R.
    Wu, H.
    Peng, Y.
    Wang, L.
    Li, L.
    Yoon, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S853 - S853
  • [43] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study
    Kato, K.
    Xu, R-H.
    Oh, D-Y.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Xu, H.
    Sheng, T.
    Barnes, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S1456 - S1456
  • [44] Phase III, randomized study of docetaxel (T) plus capecitabine (X) (TX) followed by cyclophosphamide (C) plus epirubicin (E) plus X (CEX) vs. T followed by C plus E plus fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): An interim safety analysis.
    Joensuu, H
    Hemminki, A
    Tanner, M
    Paija, O
    Kokko, R
    Asola, R
    Johansson, K
    Bono, P
    Elomaa, I
    Kellokumpu-Lehtinen, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 57S - 57S
  • [45] Analysis of circulating tumor DNA (ctDNA) identifies on-treatment genomic alterations in a phase 2 study of veliparib plus FOLFIRI ± bevacizumab vs. placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer (mCRC)
    Ramathal, Cyril Y.
    Murphy, Erin
    Asque, Elizabeth
    Grundstad, Arne Jason
    Ansell, Peter
    He, Lei
    Luo, Yan
    Berlin, Jordan
    Waring, Jeff
    CANCER RESEARCH, 2019, 79 (13)
  • [46] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.
    Cruz-Correa, Marcia
    Xu, Rui-Hua
    Moehler, Markus H.
    Oh, Do-Youn
    Kato, Ken
    Spigel, David R.
    Arkenau, Hendrik-Tobias
    Tabernero, Josep
    Zimina, Anastasia V.
    Bai, Yuxian
    Shi, Jianhua
    Lee, Keun-Wook
    Hirano, Hidekazu
    Wyrwicz, Lucjan S.
    Pazo Cid, Roberto
    Xu, Hui
    Sheng, Tao
    Barnes, Gisoo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 290 - 290
  • [47] Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with/without peritoneal or liver metastases: A post hoc analysis of RATIONALE-305 study.
    Qiu, Miaozhen
    Luo, Huiyan
    Wang, Feng-Hua
    Wang, Feng
    He, Ming-Ming
    Xu, Sheng
    Pan, Xiaoxi
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 414 - 414
  • [48] Early- vs. late-onset treatment using abiraterone acetate plus prednisone in chemo-naive, asymptomatic ormildly symptomatic patients with metastatic CRPC after androgen deprivation therapy
    Merseburger, Axel S.
    Ruessel, Christoph
    Belz, Hanjo
    Spiegelhalder, Philipp
    Feyerabends, Susan
    Nguyen Tran
    Kruetzfeldt, Katrin
    Baurecht, Werner
    Boegemann, Martin
    AKTUELLE UROLOGIE, 2020, 51 (06) : 562 - 571
  • [49] FINAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF SUNITINIB PLUS FOLFIRI VS. PLACEBO PLUS FOLFIRI IN FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Carrato, A.
    Swieboda-Sadlej, A.
    Staszewska-Skurczynska, M.
    Lim, R.
    Roman, L.
    Shparyk, Y.
    Bondarenko, I.
    Lin, X.
    Lechuga, M. J.
    Tursi, J. M.
    Sun, Y.
    De la Cruz, J. A.
    Jonker, D.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 19 - 19
  • [50] A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus adevofir dipivoxil vs. pegylated interferon-alfa-2a plus placebo vs. adevofir dipivoxil for the treatment of chronic delta hepatitis: The hep-net/international delta hepatitis intervention trial (HID-IT)
    Yurdaydin, Cihan
    Wedemeyer, Heiner
    Dalekos, George
    Erhardt, Alexander
    Cakaloglu, Ya
    Degertekin, Ha
    Gurel, Sa.
    Zeuzem, Stefan
    Zachou, Kalliopi
    Bozkaya, Hakan
    Dienes, Hans P.
    Bock, Thomas
    Manns, Michael P.
    HEPATOLOGY, 2006, 44 (04) : 230A - 230A
12345